- Patient-derived ‘in vitro’ data revealed, hinting at potential for global clinical trials
- Back-to-back SITC and BioEurope appearances in November, with global partnering talks continuing

Y-Biologics announced on October 20 that it will present two study findings on immuno-oncology therapies developed using its ‘Multi-AbKine’ multi-antibody–cytokine fusion platform in poster presentations at the Society for Immunotherapy of Cancer (SITC 2026) Annual Meeting, to be held from November 4 to 8.

SITC is the world’s largest immuno-oncology conference, bringing together anticancer drug developers, research institutions, and specialist researchers from around the globe to share the latest research findings and clinical development trends in immuno-oncology.

At the conference, Y-Biologics plans to present preclinical findings for ‘AR170 (PD-1×VEGF×IL-2v)’ and ‘AR166 (PD-1×LAG-3×IL-2v),’ two key candidates developed using Multi-AbKine. The findings will highlight further progress based on research presented at the American Association for Cancer Research (AACR 2026) Annual Meeting in April.

In particular, the company plans to disclose selected ex vivo translational research data generated using tissue samples from actual patients. Such research can provide more concrete evidence of a candidate’s potential activity in clinical settings, increasing the prospects for early technology transfer.

Y-Biologics will also attend ‘BIO-Europe 2026,’ Europe’s largest biotechnology partnering event, in November. Building on the findings presented at the conference, the company plans to hold partnering meetings with global pharmaceutical companies to advance discussions on technology transfer and joint research.

“The competitiveness of preclinical-stage drug candidates depends on how convincingly their potential application in patients can be demonstrated. At this conference, we will demonstrate the technological strengths of our pipeline through research findings, including data from patient-derived tissues,” a Y-Biologics official said.

[Link]